A real-world assessment of tolerability and treatment outcomes of COVID-19 monoclonal antibodies administered in pregnancy - 30/04/22
Plan
P.N. receives speaker fees from Regeneron and Medscape. The remaining authors report no conflict of interest. |
|
No funding was received for this work. |
Vol 226 - N° 5
P. 743-745 - mai 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.